Powered by

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

Jan 09, 2019 - PR Newswire

PR Newswire

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided a pipeline update and announced its 2019 financial guidance at the 37th annual JP Morgan Healthcare Conference.

"Looking ahead, our ENHANZE business is gaining momentum with key product development milestones expected this year, including potential FDA approval of a subcutaneous formulation of Herceptin® and regulatory submissions for ...